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ABSTRACT 
Background 
Kidney disease is common in heart failure (HF) and has been found to be associated with 
worse outcomes. The impact of different degrees of chronic kidney disease (CKD) in HF, as 
well as the link to, and impact of CKD in HF with reduced (HFrEF), the newly defined mid-
range (HFmrEF) and preserved ejection fraction (HFpEF) have been uncertain. Studies of 
worsening renal function (WRF) in the various EF groups are lacking. HF treatment of 
HFrEF is well defined, while we lack knowledge of the effect of heart failure treatment in 
HFpEF, HFmrEF and in patients with HF and CKD.  
 
Aims 
1. To examine prevalence and prognostic impact of different degrees of kidney dysfunction in 
unselected HF patients.   
2. To perform a comprehensive comparison of CKD in HF with HFpEF, HFmrEF and HFrEF 
with regards to prevalence, clinical correlates and prognosis.   
3. To examine the risk for and impact of WRF in HFpEF, HFmrEF and HFrEF.   
4. To analyze the association between mineralocorticoid receptor antagonist (MRA) 
treatment and outcome in patients with myocardial infarction (MI) and HF in relation to EF 
groups and CKD. 
Prevalence and prognostic impact of kidney disease in heart failure 
We studied 47,716 patients in the Swedish Heart Failure Registry (SwedeHF) 2000-2013. 
Patients were divided into five renal function strata based on estimated glomerular filtration 
rate (eGFR). 51% of the patients had eGFR < 60 ml/min/1.73 m2 and 11% had eGFR < 30 
ml/min/1.73 m2.  The mortality risk increased with decreasing eGFR and persisted after 
adjusting for differences in baseline characteristics, severity of heart disease and medical 
treatment. 
Associations with and prognostic impact of CKD in HFpEF, HFmrEF and HFrEF 
Of 40,230 patients with measured EF in SwedeHF, 22% had HFpEF, 21% had HFmrEF, and 
57% had HFrEF, with a CKD prevalence of 56%, 48%, and 45%, respectively. Associations 
between covariates and CKD were similar in all EF groups. There was higher mortality in all 
EF groups in patients with CKD. After adjustment, CKD was more strongly associated with 
death in HFrEF and HFmrEF than in HFpEF.  
WRF in different EF categories  
After merging the SwedeHF registry with the laboratory data in Stockholm Creatinine 
Measurement (SCREAM) database, 7,154 patients in Stockholm between 2006-2010 were 
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studied. After discharge, the risk for WRF was higher in HFpEF than in HFmrEF and HFrEF. 
Variables related to more severe HF were predictive of WRF. WRF within year one after the 
index-HF event was strongly associated with long-term mortality, but in HFpEF only with the 
most severe WRF. 
Outcome in MI patients with HF with or without MRA treatment 
Patients with MI and HF registered in the Swedish national myocardial infarction registry, 
SWEDEHEART, between 2005-2014, were studied. Of 45,071 patients with MI and HF, 
10% were treated with MRA. Patients with reduced EF < 40% were more often treated with 
MRA compared to mid-range EF 40-49% and normal EF > 50%.  Of patients with CKD, 9% 
received MRA. After adjustment, MRA use was associated with a lower mortality in patients 
with EF < 40% but not with EF > 50% while the association between MRA use and outcome 
was similar regardless of presence or not of CKD.  
Conclusions 
In unselected HF patients, half of the patients have at least moderate renal dysfunction. There 
is a strong graded association between renal dysfunction and both short- and long-term 
outcome. CKD is slightly more common in patients with HFpEF but is associated with 
similar covariates regardless of EF. CKD is strongly associated with mortality regardless of 
EF group, although less strongly in HFpEF than in HFmrEF and HFrEF. The long-term risk 
of WRF is high in HF and especially in HFpEF. WRF within one year of discharge is a strong 
negative prognostic factor in all EF groups during long term follow-up, although in HFpEF 
only in those with the most severe WRF. In patients with MI and HF, MRA treatment is 
associated with better long-term survival in patients with reduced but not with preserved EF, 
while the association between MRA use and outcome seems to be similar regardless of 
presence or not of CKD.  
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SAMMANFATTNING  
Bakgrund 
Nedsatt njurfunktion är vanligt vid hjärtsvikt och har visat sig vara en negativ prognostisk 
faktor. Betydelsen av olika grader av sänkt njurfunktion vid hjärtsvikt samt sambandet mellan 
och betydelsen av njursvikt vid hjärtsvikt med sänkt (HFrEF), lätt sänkt (HFmrEF) och 
bevarad ejektionsfraktion (HFpEF) är okänt. Studier av försämring av njurfunktionen över tid 
(WRF) i de olika EF grupperna saknas. Hjärtsviktsbehandling vid HFrEF är väl studerad, 
medan vi saknar kunskap om hjärtsviktsbehandling vid HFpEF och HFmrEF och vid 
hjärtsvikt med samtidig njursvikt. 
Syfte 
1. Att undersöka förekomsten och prognostisk betydelse av olika grader av nedsatt 
njurfunktion hos oselekterade hjärtsviktspatienter.   
2. Att göra en jämförelse av njursvikt vid HFpEF, HFmrEF och HFrEF avseende förekomst, 
kliniska samband och prognostisk betydelse.   
3. Att undersöka förekomst av och den prognostiska betydelsen av WRF vid HFpEF, 
HFmrEF och HFrEF.  
4. Att undersöka associationen mellan behandling med mineralkortikoidreceptorantagonister 
(MRA) och utfall hos patienter med hjärtinfarkt och hjärtsvikt i relation till EF grupp och 
förekomst av njursvikt.  
Prevalens och prognostisk betydelse av njursvikt vid hjärtsvikt 
Vi studerade 47 716 patients i det Svenska Hjärtsviktsregistret (Riks-Svikt) 2000-2013. 
Patienterna blev indelade i fem njurfunktionsgrupper baserat på estimerat glomerulär 
filtrationshastighet (eGFR). 51 % av patienterna hade minst måttlig njurfunktionsnedsättning 
(eGFR < 60 ml/min/1.73 m2) och 11 % hade minst avancerat nedsatt njurfunktion (eGFR < 
30 ml/min/1.73 m2).  Mortalitetsrisken ökade med sjunkande eGFR och kvarstod efter 
justering för skillnader i bakgrundsvariablerna, svårighetsgraden av hjärtsjukdomen och 
medicinsk behandling. 
Associationer med och prognostisk betydelse av njursvikt vid HFpEF, HFmrEF och 
HFrEF 
Av 40 230 patienter i Riks-Svikt hade 22% HFpEF , 21% HFmrEF och 57% HFrEF med en 
prevalens av njursvikt på 56%, 48%, and 45%. Det var liknande associationer mellan 
bakgrundsvariablerna och njursvikt i alla EF grupperna. Det var en högre mortalitet hos 
patienterna med njursvikt. Efter justering var njursvikt starkare associerat med död och 
predicerade död starkare vid HFrEF och HFmrEF än vid HFpEF. 
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Försämring av njurfunktion över tid vid olika EF kategorier 
Efter samkörning av Riks-Svikt med data från Stockholm Creatinine Measurement 
(SCREAM) databasen, studerades 7154 patienter i Stockholm från åren 2006-2010. Risken 
för WRF var högst hos patienterna med HFpEF. Faktorer relaterade till svår hjärtsvikt var 
också relaterade till WRF. WRF under det första året var starkt associerat med mortalitet över 
lång tid, dock vid HFpEF var det enbart vid svårare WRF.  
Patienter med hjärtinfarkt och hjärtsvikt med och utan behandling med MRA 
Patienter med hjärtinfarkt och hjärtsvikt registrerade i det Svenska Hjärtinfarktsregistret 
(SWEDEHEART), 2005-2014 studerades. Av 45 071 patienter med hjärtinfarkt och 
hjärtsvikt behandlades 10% med MRA. Patienter med sänkt EF < 40% hade oftare MRA 
behandling jämfört med patienter med EF 40-49% och bevarad EF > 50%.  Av patienterna 
med njursvikt fick 9% MRA behandling. Efter justering var MRA behandling associerat med 
lägre dödlighet hos patienter med EF < 40% och EF 40-49% men inte vid EF > 50% medan 
risken för död med MRA behandling var oförändrad oberoende av förekomst av njursvikt. 
Slutsatser 
Hälften av alla oselekterade hjärtsviktspatienter har minst måttligt nedsatt njurfunktion. Sänkt 
njurfunktion har en graderad association med prognosen på kort och lång sikt. Njursvikt är 
något mera vanligt vid HFpEF, men är associerat med samma variabler oberoende av EF 
grupp.  Njursvikt är starkt associerat med mortalitet i alla EF grupper, men har en mindre 
stark prognostisk betydelse vid HFpEF än vid HFmrEF och HFrEF. Det är en hög risk för 
försämring av njurfunktionen över tid vid hjärtsvikt, särskilt vid HFpEF. WRF under första 
året efter en hjärtsviktshändelse är en stark negativ prognostisk faktor, dock vid HFpEF 
enbart vid svårare WRF. Hos patienter med hjärtinfarkt och hjärtsvikt är MRA behandling 
associerat med förbättrad överlevnad vid sänkt men inte vid bevarad EF. Oberoende av 
förekomst av njursvikt så ser associationen mellan MRA behandling och dödlighet ut att vara 
oförändrad. 
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INTRODUCTION 
Background 
Heart failure (HF) and kidney disease are common diseases that often appear concomitantly 
and may lead to one another (1). The prevalence of these conditions is increasing due to a 
population with increasing age and comorbidities and improved treatment of acute 
myocardial infarction (MI) (2). Both HF and kidney disease have a severe impact on the 
patients’ prognosis and patients with severe failure in both organs have the shortest lifespan 
(3). It is still a challenge to understand the complexity of these syndromes and how to 
optimally treat these patients that historically have been excluded from clinical trials (4).   
 
Prevalence of kidney failure in heart failure  
There is a high prevalence of kidney dysfunction among patients hospitalized for acute heart 
failure (AHF) varying from 30 % to 70 % depending on the definition of kidney disease (5-
8). Patients with HF that are not hospitalized tend to have a lower prevalence of chronic 
kidney disease (CKD) (6). Many previous studies of kidney function in HF patients have 
been limited by inclusion of highly selected randomized controlled trial patients or small 
sample sizes (9, 10). In studies I-III kidney dysfunction and worsening renal function (WRF) 
are studied in unselected HF patients that we encounter in daily clinical practice.   
 
The Cardiorenal syndrome  
In 1931 an article was published describing increased venous pressure and the association 
with impaired renal blood flow in dogs (11). During the subsequent years the heart and 
kidney function were reported to be connected by hemodynamic factors (12). The 
concomitant syndrome of HF and kidney disease was defined as the cardiorenal syndrome 
(CRS) in 2008 by Ronco and his colleagues as a mean for future studies (13). The cardiorenal 
syndrome describes how the heart and kidney are closely linked together by hemodynamics, 
neurohormones and the sympathetic nervous system (14) (Figure 1).  
CRS type 1 was defined as acute heart failure leading to acute kidney injury ( AKI) caused by 
hemodynamic changes with forward and backward failure, sympathetic nervous system 
activation, neurohormonal activation with renin-angiotensin-aldosterone system (RAAS) 
activation, hypothalamic-pituitary stress reaction, inflammation and immune cell signaling, 
systemic endotoxemic exposure from the gut and infections and iatrogenesis (15).  High 
central venous pressure (CVP) has since long been known to affect the kidneys (11) and renal 
venous congestion is believed to be the most important hemodynamic factor driving WRF in 
patients with HF (16). It has also been found that increased intra-abdominal pressure is 
common in acute decompensated HF and is associated with impaired kidney function (17).  
Ida Löfman 
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Figure 1  
       
 
 
CRS type 2 includes progressive CKD resulting from chronic heart failure (CHF), with many 
of the same mechanisms as in CRS 1 where multiple episodes of decompensation contribute 
to progress of both HF and CKD (18). The neurohormonal activation plays an important part 
in CRS, where Angiotensin II, a potent stimulator of the sympathetic nervous system, 
increases systemic vascular resistance, venous tone, sodium reabsorption and congestion and 
has a trophic effect on cardiomyocytes and renal tubular cells leading to cellular hypertrophy, 
apoptosis and fibrosis (19). Aldosterone promotes inflammation and fibrosis in the heart and 
kidney (20) and activation of the sympathetic system leads to HF progression as adrenergic 
receptors in the kidney increase sodium reabsorption and further RAAS stimulation (21). 
Inflammatory activation with increase of cytokines and endothelial activation in HF may also 
affect the kidneys (22, 23). Diuretic resistance which may lead to further deterioration of 
heart and kidney function by increased congestion, has recently been shown to be caused 
primarily by tubular resistance (24). 
CRS type 3 is where an episode of AKI precipitates and contributes to the development of HF 
by inflammatory mediators, oxidative stress, apoptosis and activation of neuroendocrine 
systems combined with volume overload, metabolic acidosis, retention of uremic toxins, 
hyperkalemia and hypocalcemia (25). Experimental data implies that cardiac injury may be 
induced partly by cytokines in AKI (26).  
CRS 4 is defined as primary CKD leading to a chronic impairment of cardiac function, with 
ventricular hypertrophy, diastolic dysfunction, and/or increased risk of adverse cardiovascular 
events (27). In CRS 4 comorbidities, volume overload, uremia, inflammation, malnutrition, 
Metra et al. The role of the kidney in heart failure                                                       
Eur Heart J. 2012                                                                                             
Reproduced with permission from Oxford University Press  
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calcium-phosphate abnormality, neurohormonal activation, oxidative stress and endothelial 
dysfunction play a role in the pathogenesis.  
Finally CRS type 5 is defined as concomitant cardiac and renal dysfunction in the setting of 
different systemic disorders. Here one small study has suggested a possible relationship 
between endotoxin levels and renal cell death in septic patients (28). Although the CRS types 
represent a thorough theoretical model, it has its limitation regarding pathophysiologic and 
subclinical parallel changes. The bidirectional simultaneous relationship between the heart 
and kidney is complex and there is still limited understanding of the pathophysiologic link 
between renal dysfunction and HF. The relation to CKD may even be different in HF with 
preserved (HFpEF) and reduced ejection fraction (HFrEF) (29). In study III we examine the 
association between different types of HF with subsequent WRF. 
Definition and diagnosis of kidney disease 
Measurement of creatinine is the easiest way to diagnose kidney disease. Creatinine is 
affected by age, muscle mass and hydration which is why estimated glomerular filtration rate 
(eGFR) is a more reliable measure. In earlier large studies of HF and CKD, the diagnosis of 
kidney disease were defined by a certain level of creatinine or were mainly based on 
diagnostic codes (8, 30, 31) and there were a lack of studies of non-selected contemporary HF 
populations looking at different eGFR groups. 
Both the simplified Modification of Diet in Renal Disease (sMDRD) and The Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) take into account age and sex, but 
CKD-EPI has been shown to be the most accurate method of estimating glomerular filtration 
rate in HF (32). When studying kidney dysfunction the patients can be divided in five kidney 
function categories by using the criteria from the National Kidney Foundation, Kidney 
Disease Improving Global Outcomes (KDIGO) with normal (GFR > 90 ml/min/1.73 m2), 
mildly decreased (GFR 60-89 ml/min/1.73 m2), moderately decreased (GFR 30 – 59 
ml/min/1.73 m2), severely decreased GFR (GFR 15 – 29 ml/min/1.73 m2), and kidney failure 
(GFR < 15 ml/min/1.73 m2).  
According to the KDIGO guidelines, CKD is defined as abnormalities present for over 3 
months of kidney structure or function and the classification is also based on cause and 
amount of albuminuria (33) ( Figure 2). However, CKD is most often defined as eGFR < 60 
ml/min/1.73m2 which has been found to be associated with increased mortality (34). In study 
I we study the prevalence of the different eGFR strata in HF and their impact on prognosis 
while in study II we study the prevalence of CKD in the different EF groups. 
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Figure 2 
 
 
 
Biomarkers for kidney dysfunction in HF 
Biomarkers associated with CKD have also been found to predict prognosis in patients with 
HF illustrating the close relationship between the heart and kidney function. 
In clinical practice Cystatine C, an endogenous cysteine proteinase inhibitor produced by 
nucleated cells, is well established as a biomarker for kidney dysfunction and is particularly 
well studied in AHF and is associated with prognosis (35, 36).  
Urea increase in both CKD and HF by low eGFR, hemodynamics, cachexia and muscular 
atrophy and has been found to be a strong predictor of mortality (37).  
Plasma levels of natriuretic peptides reflect atrial and ventricular filling pressures and 
increase therefore in decongested HF patients and in CKD because of fluid retention and 
reduced renal elimination (38, 39). NT-proBNP has been found to predict hospitalization and 
mortality and reduction of NT-proBNP is associated with reduced risk for hospital stay for 
HF worsening (40, 41).  
Biomarkers predictive of renal dysfunction have also been found to be predictive of new HF. 
Albuminuria has in population studies been found to predict HF (42, 43). Albuminuria is also 
observed in patients with HF and is thought to be secondary to glomerular and tubular 
damage in HF, reflecting the cardio renal connection (44) and has been shown to be a strong 
Green: low risk (if no other markers of kidney disease, no CKD),                    
yellow: moderate risk, orange: high risk, red: very high risk                                                               
Reproduced with permission from Elsevier 
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independent risk factor alongside eGFR in HF (45). We have sparse knowledge of the link 
between CKD and the development of HF in the different EF groups with their different 
pathogenesis and phenotypes.  In one recent study of 4 large community based cohorts, 
biomarkers of renal dysfunction, endothelial dysfunction and inflammation were associated 
with incident HFrEF while only natriuretic peptides and urinary albumin to creatinine ratio 
were associated with HFpEF (46). 
Comorbidities in HF and CRS 
Comorbidities are frequent in HF, they may be the cause of both HF and CKD and they may 
also be a result of CRS as in hypertension and anemia. Anemia and impaired iron metabolism 
are important in CRS (47) and may have a negative impact on both hemodynamics and 
endothelial function (48).  Arteriosclerotic disease may lead to an acceleration of CRS, being 
a common cause of both HF and CKD while CKD is a known risk factor for arteriosclerotic 
disease (49, 50).  
In an analysis of the European Heart Failure Pilot survey, which included 3,226 patients, the 
majority had a least one comorbidity, the most prevalent being CKD, anemia, and diabetes 
(51). Results showed that comorbidities were independently associated with higher age, 
higher NYHA class, ischemic etiology of HF, higher heart rate, history of hypertension and 
AF and that only diabetes, CKD, and anemia were associated with a higher risk of mortality 
and hospitalization. In the ADHERE database  the frequency of common risk factors for renal 
dysfunction, such as hypertension and diabetes increased when GFR decreased and clinical 
atherosclerosis, as manifested by coronary artery disease or peripheral vascular disease was 
more common with WRF (7). However there has been a lack of understanding of 
comorbidities over the spectrum of CKD classes and in the different EF groups. In study I 
we study the impact of renal dysfunction in relation to the various comorbidities and in study 
II we study the factors associated to CKD in different EF groups. 
CKD and EF categories 
HF with reduced EF 
Most studies have described CKD and WRF in HFrEF (5, 52, 53). The presence of CKD has 
been found to be independent of EF, as in a retrospective analysis of the Studies of Left 
Ventricular Dysfunction (SOLVD) where the patients with CKD had more advanced 
symptoms measured by NYHA class but there was no significant difference in average left 
ventricular ejection fraction (LVEF) between those with and without CKD (9). 
HF with preserved EF 
Earlier studies have often not differentiated between HFpEF and HFrEF (2) and have 
included highly selected patients where CKD has been examined only as part of a general 
Ida Löfman 
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comorbidity burden (54).  When studied, HFpEF was earlier variably defined as EF > 40-
55% (55, 56). HFpEF is a heterogeneous syndrome that has been poorly understood. 
Compared to HFrEF which has an extensive evidence based treatment algorithm, HFpEF has 
to date no evidence based treatment (57). Patients with HFpEF are frequently female and 
older and seem to have more comorbidities than patients with HFrEF (58, 59). In a Swedish-
French study of 539 HFpEF patients, the comorbidities in HFpEF included hypertension 
(78%), atrial fibrillation/flutter (65%), anaemia (51%), renal dysfunction (46%), CAD (33%), 
diabetes (30%), lung disease (25%), and cancer (16%) (60). It is still unclear whether HFpEF 
is a separate syndrome dominated by diastolic dysfunction or primarily a manifestation of age 
and age-related co-morbidities, obesity, and deconditioning. A paradigm was presented in 
2013, where the pathogenesis of HFpEF in contrast to HFrEF was thought to be driven by 
comorbidities (61) (Figure 3). The link to CKD is still uncertain, CKD in HFpEF may also be 
a reflection of higher age and comorbidity or it may evolve independently. HFpEF on the 
other hand seem to be involved in progressive kidney dysfunction by several mechanisms. 
HFpEF is thought to be associated with endothelial dysfunction (62) and inflammation (63) 
and has a high proportion of right ventricular dysfunction, all leading to CKD with a possible 
bidirectional effect (64) (Figure 4). 
Figure 3 
        
 
 
In HFPEF, myocardial dysfunction and remodeling are driven by endothelial oxidative 
stress. In HFREF, oxidative stress originates in the cardiomyocytes. In advanced HFREF, 
both mechanisms get superimposed.                                                                          
Paulus et al, A novel paradigm for preserved ejection fraction, JACC 2013. 
Reproduced with permission from Elsevier                                                       
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Figure 4 Proposed relationship between renal dysfunction and HFpEF  
 
 
 
 
 
HF with mid-range EF 
According to earlier guidelines, patients with an EF in the range 35–50% had probably 
primarily mild systolic dysfunction with no clear recommendations regarding treatment (65).  
HF with mid–range ejection fraction (HFmrEF) has increasingly been viewed as a separate 
category (56, 66, 67) and was defined as a distinct EF 40-49% phenotype in particular need 
of further study in the European Society of Cardiology Heart Failure Guidelines of 2016 (57).  
We had previously very little knowledge of this middle group, if it was a separate entity or 
merely part of a continuum between HFrEF and HFpEF. The link with CKD was poorly 
understood and there were no studies comparing HFpEF, HFmrEF and HFrEF with regard to 
CKD.  
In study II and III we examine CKD and WRF in the different EF groups. 
Worsening renal function 
Decreasing GFR is frequent in HF. In the general population renal function usually declines 
by 0.5-1.0 ml/min/1.73m2 per year, while in chronic HF, GFR has been found to decrease 2-3 
The direction of causality may prove to be in the opposite direction and most probably will be 
bidirectional. IL‐6, interleukin‐6; TNFα, tumor necrosis factor‐α; sST2, soluble ST2; ROS, reactive 
oxygen species; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; PKG, protein kinase 
G; TGFβ, transforming growth factor‐β.                                                                                                                                                                  
Ter Maaten Eur J Heart Fail 2016 Reproduced with permission from Wiley. 
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times faster (68, 69). During acute hospitalization for HF, renal function may deteriorate 
substantially faster which has been found to be an important risk factor (70).  
The definition of WRF varies between different studies and publications, and is usually 
defined as either 26.5 µmol/l (0.3 mg/dl) increase in creatinine or 20-25% increase in eGFR 
from baseline (70). In nephrology decreasing renal function is referred to as AKI, but here 
both the time aspect of increase in creatinine, either within 48 hours or within 1-7 days, and 
the urinary production is taken into consideration (71). 
WRF occurs frequently among hospitalized patients. In one study of 1,004 patients 
hospitalized with HF, WRF developed in 27% of the cases and several studies have shown 
increased mortality risk in HF patients with WRF (72, 73).  
Patients hospitalized with AHF and transient WRF have been found to have similar prognosis 
as patients with preserved kidney function while patients with persistent WRF have a worse 
prognosis (74). As patients with transient WRF have signs of hemoconcentration, transient 
WRF seems to primarily be caused by decongestion by diuretics and may not represent 
kidney damage (75). On the other hand WRF in combination with congestion has sinister 
prognosis, as shown in the study of Metra et al. where HF patients with WRF and congestion 
had more than doubled risk for death compared to the patients with WRF and no congestion 
(76).  
Prior HF, diabetes, baseline creatinine, high systolic blood pressure and anemia have earlier 
been found to be predictors of in-hospital WRF (72, 77). There is little knowledge of WRF 
and its predictors after discharge and in patients with CHF.  WRF after discharge has mostly 
been examined in the early phase after discharge and has been found to be a stronger 
predictor for outcome than in-hospital WRF (77). One small study noted that WRF at 1 year 
after discharge was associated with increased long term mortality during a mean follow-up at 
35 months (78). Another study of 1,216 patients with CHF found that 13 % of the patients 
developed WRF during the following 6 months, and the predictors for WRF included thiazide 
diuretics, vascular disease and baseline urea (79).  
To date there have been no studies of WRF after discharge comparing WRF in the different 
EF categories in an unselected HF population. In study III, we analyze the risk for long-term 
WRF and prognostic impact of WRF in patients in HFpEF, HFmrEF and HFrEF. 
Prognosis 
Despite all modern treatment, mortality remains high (80). Most previous studies examined 
short-term prognosis in both HFrEF and HFpEF, whereas data on long-term follow-up has 
been lacking (7, 81, 82). The comorbidity burden and increasing age contribute to the poor 
prognosis in HF (83). There are many variables that predict both hospitalization and mortality 
(84, 85), and CKD has been found to be an important independent risk factor (86). In a study 
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of Hillege et al in 2000, it was found that patients with advanced HF and with moderate to 
severely decreased eGFR had almost three times the mortality risk as patients with mildly 
decreased eGFR (87). The high mortality risk may be due to several factors. High CVP which 
is common in CRS has been shown to be associated with mortality (16). In CKD there are 
numerous factors associated to increased cardiovascular risk including hypertension, 
increased filling pressures, inflammation, oxidative stress, increased lipid levels, acidosis, 
deranged calcium-phosphate balance and anemia (49).  
Although there is a known increased mortality risk with CKD in HF, earlier studies had 
divergent findings concerning the importance of CKD in HFpEF compared to HFrEF (5, 88, 
89). Regarding CKD and prognosis in HFmrEF, there was no data. In study II we study the 
different EF groups and analyze the impact on prognosis of CKD in the different EF 
categories. 
Treatment of HF patients with CKD  
RAAS blockers and beta blockers 
Patients with low eGFR are less often treated with guidelines recommended heart failure 
treatment, because of fear of or proven deterioration of the kidney function. Caution is 
recommended when treating patients with severely depressed kidney function and these 
patients have systematically been excluded from randomized clinical trials (57).  
However, in a cohort of 754 patients, Angiotensin converting enzyme inhibitors (ACEi) and 
beta blockers were associated with similar reductions in mortality in patients with and 
without renal insufficiency (53). In a sub-analysis of the Valsartan in Heart Failure Trial 
(Val-Heft), the effect of valsartan on mortality did not differ in patients with and without 
CKD (90). Even subgroup analyses from the Heart Outcomes Prevention Evaluation (HOPE) 
and the Cardiac Insufficiency Bisoprolol Study II (CIBIS II) trial confirmed that ramipril and 
bisoprolol were equally efficacious and safe in patients with and without mild to moderate 
renal insufficiency (91, 92). Treatment with RAAS blockade may lead to increase in 
creatinine and WRF by dilation of the efferent arteriole and reduced glomerular perfusion 
(93). In HFrEF, the potential negative impact of WRF has been shown to be balanced by the 
beneficial effect of the RAAS blockade, in contrast to HFpEF where WRF has been 
associated with increased risk for HF hospitalization and death without any demonstrable 
survival benefit from RAAS blockade (94-96).  
Mineralocortocoid receptor antagonists  
As aldosterone promotes inflammation and fibrosis, mineralocortocoid receptor antagonists 
(MRA) is a hypothetically appealing treatment especially in HFpEF where inflammation and 
hypertension is common (97). 
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Aldosterone regulates sodium and potassium homeostasis but can also initiate an 
inflammatory response causing fibrosis of the heart, vessels and kidneys (97). The 
aldosterone receptor antagonists spironolactone and eplerenone have been shown to reduce 
morbidity and mortality among patients with HFrEF and among patients with acute MI 
complicated by left ventricular dysfunction and HF (98, 99). Inflammation and fibrosis are 
believed to be part of the pathogenesis of HFpEF (61), which is why MRA may represent a 
possible treatment directly affecting the progress of the disease. Although the Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study 
of aldosterone blockade in HFpEF did not show any positive effects on outcome, post-hoc 
regional analyses indicate beneficial effects in the American patients (100, 101). When 
treating patients with CKD there is a risk of WRF and hyperkalemia, although a sub-analysis 
of the eplerenone treatment study of patients with HF in NYHA class II showed that 
eplerenone still had survival benefit (102). 
There has been a lack of studies of treatment with MRA in unselected patients with HF and 
CKD in real life and we have little knowledge of MRA treatment in patients with HFpEF and 
HFmrEF. In study IV we examine the impact of MRA treatment in patients with MI and HF, 
in different EF groups and with and without CKD. 
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AIMS 
The main aim of the thesis was to examine the prevalence of kidney dysfunction in 
unselected HF patients in relation to different EF categories and to examine the impact of 
kidney dysfunction on survival in HFpEF, HFmrEF and HFrEF.  
 
The specific aims were 
 
1. To determine the prevalence of different degrees of kidney dysfunction and to examine 
their association with short- and long-term outcome in a large unselected contemporary HF 
population and some of its subgroups (Study I).  
 
2. To perform a comprehensive comparison of CKD in HFpEF, HFmrEF and HFrEF with 
regard to prevalence, clinical correlates and long-term prognostic role (Study II).  
 
3. To compare the long-term incidence of, associations with and prognostic impact of WRF 
in HFpEF, HFmrEF and HFrEF (Study III).  
 
4. To assess the use of MRA and the association between MRA treatment and outcome in 
patients with MI and HF in different EF groups and in the absence and presence of CKD 
(Study IV).  
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PATIENTS AND METHODS  
Data sources  
Study I, II and III  
The Swedish heart failure register (SwedeHF) has since 2000 included patients with HF and 
offers a unique possibility to study a large cohort of unselected HF patients (103). It is a web 
based national quality register including HF patients, with 54% coverage of all patients 
hospitalized with HF as the main diagnosis in Sweden according to the latest report in 2015.  
The majority of the patients (91%) are registered at hospital, the remaining in the primary 
care. Inclusion criteria are clinician-judged HF and approximately eighty variables are 
recorded at discharge or during visit to a physician or health care team. Variables in the 
registry include baseline description of the patients, risk factors, history of heart disease, 
cardiac interventions, cardiac evaluation with electrocardiogram and echocardiogram, 
laboratory tests at discharge or at the out-patient visit and medication. Registration of 
hemoglobin and creatinine are mandatory. The patients are informed of their participation in 
the SwedeHF and are allowed to opt out, but individual patient consent is not required. The 
register is monitored yearly; in 2015, in 8 hospitals 30 random registrations were reviewed 
and compared with the patients’ medical records. The database is managed by Uppsala 
Clinical Research Center (Uppsala, Sweden).   
Study III  
In study III we merged data from SwedeHF with the Stockholm Creatinine Measurement 
(SCREAM) database. The SCREAM cohort 2006-2011 was a collaborative project between 
Karolinska Institutet and the Stockholm County Council to assess the burden of kidney 
disease and inappropriate drug use in the region (104).  The core component of SCREAM 
was laboratory data related to kidney function. The laboratories extracted the requested 
laboratory tests for all patients who had undertaken these tests in the region. All laboratories 
used standardized methods of creatinine measurements traceable to dilution mass 
spectroscopy standards. The SCREAM database contains laboratory data of 98% of all 
patients with cardiovascular disease in Stockholm 2006-2011.  
 
Study IV  
In the fourth study we analyze data from the nationwide SWEDEHEART (Swedish Web-
System for Enhancement and Development of Evidence-Based Care in Heart Disease 
Evaluated According to Recommended Therapies) registry (105). SWEDEHEART includes 
almost all patients hospitalized for acute MI and admitted to a coronary care unit or other 
specialized facility with coverage of 96% of patients < 80 years old and around 80% of 
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elderly patients (106). The registry covers all hospitals taking care of acute cardiac patients in 
Sweden (n=72). In the acute coronary care part of the registry, more than 100 variables are 
collected prospectively including admission logistics, patient demographics, risk factors, past 
medical history, medical treatment before admission, electrocardiographic changes, 
biochemical markers, clinical investigations, medical treatment in hospital, interventions, 
hospital outcome, diagnoses and medication at discharge. Patients receive information about 
their participation in SWEDEHEART on admission and are allowed to opt out. The registry 
is monitored on a regular basis with visits to approximately 30 randomly selected hospitals 
each year, comparing data entered into SWEDEHEART with the information in the patients’ 
health records, repeatedly showing an agreement of 95-96%.  
The data in study IV was linked to the Swedish Prescribed Drug Registry, which contains all 
pharmacy-drug dispensations in the country for each unique citizen to get information of the 
prevalence of spironolactone and eplerenone in patients after discharge.   
 
In study I-IV: Mortality data was obtained by running the registries against the Population 
Register in Sweden which includes the vital status of all Swedish citizens and permanent 
residents. 
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Study populations   
Study I   
A total of 47,716 unique patients from SwedeHF 2000-2013 were studied after exclusion of 
patients with missing data on creatinine, age and with creatinine measured with methods not 
traceable to isotope dilution mass spectroscopy standards (Figure 5). 
Study II 
In total 40,230 unique patients from SwedeHF 2000-2013 were studied after exclusion of 
patients with missing data for age or creatinine, creatinine measurement by non-standardized 
methods, patients that died during hospitalization and exclusion of patients with missing data 
of EF (Figure 5). 
Study III 
In total 7,154 unique patients from SwedeHF in Stockholm 2006-2010 were studied after 
exclusion of patients with no recorded measurements of EF and no follow-up values of 
creatinine (Figure 5).  
Study IV 
A cohort  of 45,071 unique patients from SWEDEHEART 2005-2014 with acute MI and HF 
(previously known or diagnosed during hospitalization (defined as; Killip >1, administration 
of intravenous diuretics/inotropes or use of continuous positive airway pressure)) were 
studied after exclusion of patients with prior MRA use and patients that died during 
hospitalization or within 2 weeks from discharge. 
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Figure 5 Study populations, study I-III 
 
 
 
 
Methods, outcome and Statistics 
Glomerular filtration rate was estimated with the CKD-EPI equation (32).  LVEF was both in 
SwedeHF and SWEDEHEART obtained from the latest available measurement and method 
according to local practice (in Sweden generally echocardiography with the Simpson 
method). HFpEF was defined as HF with EF ≥ 50%, HFmrEF as HF with EF 40-49% and 
HFrEF as HF with EF < 40%.  
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database                              
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Study I  
The patients were divided into 5 renal function categories with normal function (eGFR ≥ 90), 
mild dysfunction (eGFR 60-89), moderate dysfunction (eGFR 30-59), severe dysfunction 
(eGFR 15-29), and end stage renal disease (eGFR < 15 ml/min/1.73 m2) based on creatinine 
obtained at discharge for hospitalized patients and at the closest date preceding an outpatient 
visit. 
Outcome was all cause mortality during up to 12 years follow-up.  
Crude survival was assessed and illustrated by Kaplan-Meier analyses. Uni- and 
multivariable Cox proportional hazard regression was used to examine the association 
between kidney function and outcome using three models: in the first model adjustment were 
made for variables possibly influencing both kidney dysfunction and outcome (age, gender, 
smoking, hypertension and diabetes), in the second model variables related to the etiology 
and severity of heart failure were added (heart failure > 6 months, ischemic heart disease 
(IHD), previous valvular intervention, non-sinus rhythm in the electrocardiogram, heart rate, 
LVEF, New York Heart Association (NYHA) class, systolic blood pressure and hemoglobin 
level)  and in the third model we also made adjustments for given treatment (ACEi, 
angiotensin receptor blockers (ARB), beta blockers, aldosterone antagonists, statins and 
cardiac resynchronization therapy (CRT)). 
 
Study II 
CKD was defined as eGFR < 60 ml/min/1.73m2, based on creatinine obtained at discharge 
for hospitalized patients and at the closest date preceding an outpatient visit. 
In the analyses of association between baseline variables and baseline CKD, the dependent 
variable was CKD. In analyses of the association between CKD and prognosis, the outcome 
was death from any cause.  
Associations between baseline variables and baseline CKD were assessed with multivariable 
logistic regression using a total of 28 clinically relevant variables: age, gender, civil status, 
care in cardiology ward, hypertension, diabetes, smoking, IHD, atrial fibrillation, valvular 
heart disease, chronic obstructive lung disease (COPD) , revascularization, hospitalization at 
diagnosis, HF duration > 6 months, NYHA class, haemoglobin, systolic blood pressure, heart 
rate, RAAS blockers, beta blockers, aldosterone antagonists, digoxin, statins, nitrats, oral 
anticoagulants, antiplatelet treatment, specialist follow-up and heart failure team follow-up.  
Pre-selected variables of interest were illustrated in a Forest plot. 
Crude survival was assessed and illustrated with Kaplan-Meier analyses. 
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Uni- and multivariate Cox proportional hazard regression analyses were used to examine the 
association between CKD and mortality and adjustments were made for the same 28 
variables as above. Analysis of interaction between CKD and EF group was performed by 
creating an interaction term in a Cox regression analysis. 
Prognostic value of kidney function, regardless of chosen cut-off value for eGFR, was 
assessed by area under the curve in ROC analyses. 
Missing data of the variables in the multivariable analyses was handled by multiple 
imputation with 10 dataset. 
Study III 
WRF was defined as > 25% decrease in estimated glomerular filtration rate (eGFR) when 
studying associations between baseline characteristics and WRF within one year and within 
five years follow-up. 
WRF was divided in 25-49% and > 50% decrease in eGFR when studying the association 
between WRF within year one and subsequent mortality up to six years follow-up. Baseline 
creatinine was obtained at the closest date preceding an outpatient visit or at discharge for 
hospitalized patients. Subsequent measurements were performed as considered indicated in 
the clinical routine. 
The associations between EF groups and subsequent WRF and between WRF within one 
year and subsequent mortality were assessed with Kaplan-Meier analyses and multivariable 
Cox regression using a total of 31 clinically relevant variables  including demography (age, 
gender, civil status, care at a cardiology clinic), risk factors (diabetes mellitus, hypertension), 
previous cardiovascular disease (IHD, atrial fibrillation, valvular heart disease), comorbidity 
(COPD), previous procedures (revascularization), characterization of HF (hospitalization at 
inclusion, HF duration over 6 month, NYHA class,  use of inotropes, CRT, physical status 
(non-sinus rhythm, heart rate (< 70,  > 70 beats per minute), systolic blood pressure (< 100, 
100-139, > 140 mm Hg), lab (Hb < 120 , > 120 g/dl), CKD ( < 30, 30-59, > 60 
ml/min/1.73m2 )), WRF during hospitalization (defined as a 25% decrease in eGFR and 26.5 
µmol/l  increase in creatinine) and medication at discharge (ACEi/ARB, beta blockers, MRA, 
digoxin, statins, nitrates, antiplatelets, anticoagulants, diuretics). In the analysis of the 
association between WRF and subsequent mortality a stepwise adjustment for baseline eGFR 
and then the remaining variables was made. 
The multi-adjusted risk for WRF > 25% within one year and within five years and the multi-
adjusted mortality risk with WRF 25-49% and WRF > 50%  in the different EF groups were 
illustrated in Forest plots. 
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Missing data was handled by multiple imputation with 20 dataset using the same variables as 
in the multivariable analyses. 
 
Study IV 
MRA use after discharge was defined as a recorded dispensation of spironolactone or 
eplerenone within 2 weeks after discharge. CKD was defined as eGFR < 60 ml/min/1.73m2.   
The outcome was all-cause mortality up to 3 years of follow-up. 
The association between the use of MRA and mortality in the different EF groups and in the 
presence or not of CKD were assessed with uni- and multivariable Cox regression analyses. 
Adjustments were made for 28 variables; center as random effect, year of admission, age, 
gender, risk factors (diabetes mellitus, hypertension), previous cardiovascular disease ( MI, 
HF, peripheral vessel disease), previous other diseases (COPD, cancer), status at presentation 
(ST-elevation, Killip > 1, atrial fibrillation), intervention and treatment (PCI,CABG, iv 
diuretics, inotropes), medication at discharge (ACEi/ARB, beta-blockers, calcium 
antagonists, diuretics, digoxin, statin therapy, antiplatelet therapy and warfarin), atrial 
fibrillation at discharge and eGFR.  
Analyses of interaction between MRA and EF groups and MRA and CKD were performed 
by creating an interaction term in the Cox regression analysis.  For continuous variables 
natural cubic splines with 4 degrees of freedom (knots) were used. 
Multiple imputation was used to create 30 imputed data sets. Incomplete variables were 
imputed using the random forest based MICE algorithm. 
A sensitivity analysis of complete cases was performed to validate the robustness of the 
results.  
Statistics in Study I and II were made in SPSS version 22, with use of STATA version 13 for 
figures in study II. In study III STATA version 14.1 was used, with SPSS version 24 for 
imputations and in study IV statistics were made with R. 
Ethical consideration 
The registries conform to the national laws and the declaration of Helsinki. The studies were 
approved by the regional ethical review boards in Linköping and Stockholm. 
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RESULTS 
Study I 
Kidney function and heart disease    
A total of 24,225 (51%) patients had at least a moderate kidney dysfunction (eGFR < 60 
ml/min/ 1.73 m2) and 5,065 (11%) at least a severe kidney dysfunction (eGFR < 30 
ml/min/1.73 m2) while 813 (2%) were classified as end stage renal disease (eGFR < 15 
ml/min/1.73 m2). Patients with lower kidney function were older, more often female and had 
more frequently had hypertension and diabetes mellitus.  
Patients with poor kidney function were more likely to have IHD. Atrial fibrillation, stroke 
and valvular heart disease were more common in those with reduced kidney function but they 
were less likely to have dilated cardiomyopathy. Patients with reduced kidney function had a 
higher likelihood of HF with a known duration of more than 6 months and were more often 
hospitalized at inclusion. Mildly symptomatic heart failure was more common in those with 
preserved kidney function and severe HF increased with worsened kidney function.  Patients 
with reduced eGFR had more often preserved LVEF, whereas in patients with preserved 
kidney function severe left ventricular systolic dysfunction (LVEF < 30%) was more 
common. 
Physical findings    
There were no major differences between the eGFR strata regarding heart rate, blood pressure 
and body mass index. Presence of left bundle branch block and QRS-width did not differ 
between eGFR-strata. The laboratory data showed that patients with low eGFR had more 
often low hemoglobin and a high potassium level and a markedly higher level of N–terminal 
pro-brain natriuretic peptide (NT-proBNP). 
Treatment 
Patients with reduced kidney function were less likely to be treated with ACEi, beta-blockers 
and aldosterone blockade. If treated, they were also less likely to receive what was considered 
to be guideline recommended target dose of ACEi, ARB and beta-blockers. Statins and 
anticoagulant treatment were used less often whereas aspirin was used more often in those 
with impaired kidney function. 
Outcome 
Half of all patients with eGFR < 15 ml/min/1.73 m2 had died after 6 months and after one 
year over 40% of those with severe kidney dysfunction and 60% of the patients with end 
stage renal disease had died (Table 1).  
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There was an increasing mortality with decreasing kidney function regardless of age, 
presence of diabetes or not, NYHA class, and hemoglobin levels.  
Although patients with HF with a duration of more than 6 months had higher one year 
mortality than patients with HF with a shorter duration (25% vs. 16%), the prognosis was 
primarily dependent on the eGFR. One year mortality in patients with normal kidney function 
was 7% in HF with duration less than 6 months vs. 8% with duration more than 6 months and 
in patients with eGFR < 15 one year mortality was 61% vs. 63%.   
During long-term follow-up, the cumulative probability of death at five years was more than 
80% in patients with at least severe kidney dysfunction (eGFR < 30) and  60% in those with 
moderate kidney dysfunction (eGFR 30-59) ( Figure 6). Even in the age group below 65 
years the prognosis was sinister with a 60% probability of death at 5 years in those with 
severe kidney dysfunction.  
Figure 6 
          
          
 
           
(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) 
strata, crude survival assessed by Kaplan-Meier analysis, log rank p<0.001.  
(B) Mortality in patients under 65 years with heart failure and different GFR strata,  
crude survival assessed by Kaplan-Meier analysis. 
Löfman et al, Open heart 2016. Reproduced with permission from BMJ. 
A 
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When adjusting for baseline variables possibly influencing both kidney dysfunction and 
outcome (age, gender, smoking, hypertension and diabetes) in model 1 the association 
between eGFR and mortality was attenuated (Table 1).  When adding HF related variables in 
model 2 the association between eGFR strata and mortality was further somewhat weakened 
but still significant. When adjusting for differences in medical treatment in model 3 the 
association between eGFR strata and mortality remained unchanged. 
Table 1 Mortality and unadjusted and adjusted mortality risk in relation to eGFR    
 eGFR≥90 
n=5251 
eGFR 60-89 
n=18 240 
eGFR 30-59 
n=19 016 
eGFR 15-29 
n=4252 
eGFR<15 
n=813 
In hospital (%) 1% 2% 3% 10% 28% 
At 6 months (%) 5% 8% 16% 35% 53% 
At 1 year (%) 7% 13% 23% 46% 62% 
Longterm (HR)(unadjusted) 1 1.85 (1.73-1.97) 3.57 (3.35-3.80) 7.72 (7.20-8.28) 11.71 (10.62-12.90) 
Model 1 (HR)(n=47545) 1 0.83 (0.77-0.89) 1.13 (1.05-1.21) 2.12 (1.96-2.29) 4.19 (3.79-4.64) 
Model 2 (HR)(n=27304) 1 0.84 (0.74-0.92) 1.10 (1.00-1.20) 1.87 (1.68-2.08) 3.26 (2.79-3.80) 
Model 3 (HR)(n=27302) 1 0.86 (0.79-0.95) 1.13 (1.03-1.24) 1.85 (1.67-2.07) 2.96 (2.53-3.47) 
 
 
 
      
 
Study II 
Patients and baselines characteristics 
Of 88,317 registrations in SwedeHF 2000 – 2013, 40,230 unique patients were included after 
applying exclusion criteria mentioned earlier. 8,875 (22%) were classified as HFpEF, 8,374 
(21%) as HFmrEF and 22,981 (57%) as HFrEF.  
CKD was more common in HFpEF than in HFmrEF and HFrEF, 56% vs. 48% and 45% 
respectively. Patients with HFmrEF were younger and less often female than HFpEF but 
older and more often female than HFrEF.  
In model 1 adjustment for baseline variables possibly influencing both kidney dysfunction and outcome (age, gender, 
smoking, hypertension and diabetes). In model 2 variables related to the etiology and severity of heart failure (heart failure 
> 6 months, IHD, atrial fibrillation, valvular heart disease, dilated cardiomyopathy, previous revascularization, previous 
valvular intervention, non-sinus rhythm in the electrocardiogram, heart rate, LVEF, NYHA class, systolic blood pressure 
and hemoglobin level) were added. In model 3 adjustment for given treatment (ACEi, ARB, beta blockers, aldosterone 
antagonists, statins and CRT) 
            Löfman et al 2016, Open heart. Reproduced with permission from BMJ                             
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In all EF categories the patients with CKD had higher age, more comorbidity and more 
severe HF. There was more hypertension, atrial fibrillation and valvular heart disease in 
HFpEF while there was more IHD in HFmrEF and HFrEF, and with higher prevalence in 
patients with CKD. There were a higher proportion of diabetes in patients with CKD, but no 
difference between HFpEF, HFmrEF and HFrEF.  
Patients had higher systolic blood pressures in HFpEF and HFmrEF and slightly higher BMI 
in HFpEF, with no major differences in the presence vs. absence of CKD. In all EF groups 
hemoglobin level decreased with lower kidney function and was lowest in HFpEF. NT-
proBNP was approximately doubled in CKD vs. non-CKD, regardless of EF and was highest 
in HFrEF. 
Figure 7 Multivariable logistic regression; Association with CKD 
       
 
OR= Odds ratio 
Löfman et al, EJHF 2017. Reproduced with permission from Wiley On-Line Library 
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Associations between covariates and CKD 
Associations were assessed between important baseline covariates and CKD, to elucidate the 
potential risk factors for CKD in the different EF groups (Figure 7). Many of the baseline 
variables were independently associated with CKD, including higher age, female sex, 
hypertension, diabetes and longer duration of HF and NYHA class. Anemia was strongly 
associated with CKD, whereas IHD and atrial fibrillation were less strongly associated with 
CKD after adjustments for covariates. Notably, the associations with CKD changed 
somewhat after multivariable adjustment, but were similar regardless of EF category.  RAAS 
blockade was associated with lower odds of having CKD while beta blockers were associated 
with higher odds. 
Associations between CKD and mortality  
Over a median (IQR) follow-up of 900 (369-1669) days, there were 10 862 deaths overall. 
Patients with CKD had a worse outcome both in the short and long term in all EF groups 
(Figure 8). In the crude survival analyses patients with HFpEF, HFmrEF and HFrEF had 
similar poor prognosis in the presence of CKD, whereas in the absence of CKD, HFpEF had 
higher one year, five years, overall and long term mortality compared to HFmrEF and 
HFrEF. CKD was less strongly associated with mortality in HFpEF than in HFmrEF and 
HFrEF in the unadjusted analysis and remained less associated with mortality after multiple 
adjustments (p for interaction < 0.001) (Table 2).           
Figure 8 Kaplan–Meier curves for mortality in HFpEF, HFmrEF and HFrEF  
       
 eGFR =estimated glomerular filtration rate.  
Löfman et al, EJHF 2017. Reproduced with permission from Wiley   
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Table 2 Association between CKD and mortality according to EF category 
Model 
HFpEF HFmrEF HFrEF 
HR 95% CI HR 95% CI HR 95% CI 
Crude 1,95 1,83 -2,08 2,64 2,46 -2,84 2,75 2,64 -2,88 
Adjusted age 1,40 1,31-1,50 1,72 1,60-1,86 1,80 1,72-1,89 
Adjusted age and gender 1,41 1,32-1,56 1,73 1,61-1,87 1,82 1,74-1,90 
Adjusted all baseline 
variables*  
1,32 1,24-1,42 1,51 1,40-1,63 1,49 1,42-1,56 
 
 
 
 
 
In ROC analyses of one year mortality, the prognostic discrimination of kidney function, 
measured as eGFR as a continuous variable, was stronger in HFrEF and HFmrEF than in the 
patients with HFpEF. 
 
Study III 
Incidence of WRF  
Of the 7,154 patients, 5,186 (72.5%) were discharged from hospital, while 1,986 (27.5%) 
patients were included at an out- patient visit. Within the first year, of patients discharged 
from hospital 41.2% developed WRF > 25% and 14.4% WRF > 50%, while of the out-
patients, 23.5% developed WRF > 25% and 6.4% WRF > 50%.  
Median (IQR) time to WRF > 25% was 174 (52-439) days in HFpEF, 207(55-498) days in 
HFmrEF and 218 (57-503) days in HFrEF and to WRF > 50% 350 (129-604) , 394 (147-772) 
and 396 (160-733)  days respectively. 
During the first year 41.6% of the patients with HFpEF vs. 34.5% and 35.4% with HFmrEF 
and HFrEF developed WRF > 25%. 
There was an increasing cumulative incidence of WRF during five year follow-up. At two 
years over 50% of the patients in all EF groups had WRF > 25%, with a slightly higher 
proportion in HFpEF and a slightly lower in HFmrEF (Figure 9) and  25% of the patients had 
WRF > 50%, even here a somewhat higher proportion in HFpEF. 
 
*age, gender, civil status, cardiology ward, specialist follow-up, heart failure team follow-up, 
hypertension, diabetes, smoking, ischemic heart disease, atrial fibrillation, valvular heart disease, 
pulmonary disease, revascularization, hospitalization at diagnosis, heart failure duration > 6 months, 
NYHA class, haemoglobin , systolic blood pressure, heart rate, RAAS blockers, beta blockers, 
aldosterone antagonists, digoxin, statins, nitrats, oral anticoagulants and antiplatelet treatment                                                                                                                                                                                   
Löfman et al, EJHF 2017. Reproduced with permission from Wiley   
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Figure 9 WRF > 25% during follow-up, stratified on different EF groups 
       
Associations between baseline variables and incident WRF 
In all EF groups the patients with WRF > 25% within the first year were older, had more 
often hypertension, atrial fibrillation, IHD, valvular heart disease, were more often 
hospitalized at inclusion, had more often higher NYHA class, more often anemia, COPD, less 
often eGFR > 60 ml/min/1.73m2 but higher NT-proBNP and were more often treated with 
MRA and diuretics. In HFmrEF and HFrEF, patients with WRF > 25% had also more 
frequently HF with duration > 6 months and only in HFrEF had the patients with WRF  more 
often WRF during hospitalization. 
In the multi-adjusted analyses, the risk for WRF > 25% during the first year was higher in 
HFpEF (reference) than in HFmrEF and HFrEF (hazard ratio (HR) (95% CI) 1.0 vs 0.890 
(0.794-0.997) and 0.870 (0.784-0.965)) and with similar trends during five years follow-up 
(Figure 10). In all EF groups, higher age, diabetes, enrolment at hospital discharge vs. as out-
patient, NYHA class, use of MRA and diuretics were associated with WRF > 25%. Even 
COPD and  anemia, HF duration over 6 months, valvular heart disease, use of CRT, low 
systolic blood pressure and treatment with digoxin were associated with WRF > 25%.  There 
were few significant interactions when stratifying for EF groups. In HFrEF but not in 
HFmrEF and HFpEF, the duration of HF was associated with WRF. 
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Figure 10 Risk for WRF within the first year and within five years, HR ( 95% CI)   
 
     
 
 
 
 
 
Associations between WRF and all-cause mortality 
Within the first year after the index-HF event, 16.3%, 15.7% and 15.6% respectively of the 
HFpEF, HFmrEF and HFrEF patients died. Patients alive and with WRF > 25% within year 
one had higher long-term mortality from year one than the patients with no WRF regardless 
of EF group. 
There were clear associations between WRF 25-49% and WRF > 50% within year one and 
mortality during follow-up, with the strongest association with WRF > 50% in all EF groups, 
both unadjusted, after adjustment for baseline eGFR and in the fully adjusted analyses. In 
WRF 25-49% there was a lower mortality risk in HFpEF (HR, 95% CI) 1.101(0.913-1.328) 
than compared to HFmrEF 1.655 (1.354-2.024) and HFrEF, 1.212 (1.06-1.386) while in 
WRF > 50% the multi adjusted mortality risk was similar in all EF groups. 
Figure 11   Mortality risk during follow-up with WRF 25-49% and WRF>50% within       
year one in different EF groups, HR (95% CI) 
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Study IV 
Treatment with MRA 
Of 45,071 patients with acute MI and HF, 4,470 (9.9%) patients had MRA prescribed at 
discharge, of which 4,269 (9.5%) had spironolactone and 204 (0.5%) had eplerenone. Those 
with MRA were somewhat younger, had more often STEMI on admission, had less often 
prior MI, HF and CKD, were  less often treated with antiplatelet treatment, beta-blockers and 
diuretics on admission and had more often severely reduced EF compared with patients with 
no MRA. They were more often treated with inotropic drugs, intravenous diuretics and 
revascularization. At discharge, patients with MRA had more ACEi/ARB and diuretics, and 
slightly more often beta-blockers compared to patients without MRA. 
Of 30,485 patients with a known LVEF, 9,895 (32.5%) had LVEF > 50%, 7,921 (26.0%) had 
LVEF 40-49% and 12,669 (41.6%) had LVEF < 40%. Patients with lower LVEF were 
generally older, had more frequently diabetes mellitus, prior MI and HF, had higher rates of 
STEMI at admission and had lower eGFR. A total of 469 (4.7%) patients with LVEF > 50% 
had MRA, while 722 (9.1%) of patients with LVEF 40-49% and 2,486 (19.6%) of patients 
with LVEF < 40% had MRA. In patients with LVEF ≥ 50%, baseline characteristics for those 
treated and not treated with MRA differed from those with LVEF 40-49% or LVEF < 40%. 
In this group, patients treated with MRA were older, had more often risk factors such as 
diabetes mellitus and hypertension, were more likely to have atrial fibrillation, and were more 
frequently treated with beta-blockers and diuretics on admission.     
Of 43,163 with known kidney function, 20,904 patients (48.4%) had eGFR < 60 
ml/min/1.73m2. Patients with CKD were older, more often female, had more frequently other 
risk factors and cardiovascular diseases. They were also less often treated with 
revascularization and ACEi/ARB, but more often treated with diuretics. A total of 1,802 
patients (8.6%) with CKD were treated with MRA vs. 2,532 (11.4 %) of the patients without 
CKD. Regardless of kidney function the relative differences in baseline characteristics and 
other treatments between patients treated with and without MRA were similar. 
Mortality 
The mortality rate was lower in patients treated with MRA during follow-up, 14.9 ((95% CI) 
14.1-15.6) vs. 17.9 (17.6-18.2) per 100 person years in untreated patients resulting in HR 
(95% CI) of 0.83 (0.78-0.88). The association between MRA treatment and mortality was 
attenuated after adjustment but still significant (HR (95% CI) 0.94 (0.89-0.99)). 
In the crude analysis when stratifying into different LVEF groups, MRA treated patients had 
lower mortality rates compared to the untreated patients in those with reduced LVEF (< 40 
%) (13.2 (12.2-14.2) vs. 19.2 (18.6-19.8) per 100 person-years) and LVEF 40-49% (10.2 
(8.6-11.8) vs. 12.2 (11.7-12.7) per 100 person years) (Figure 12). In those with LVEF > 50%, 
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MRA treated patients had higher mortality rates compared to the untreated patients (15.1 
(12.6-17.5) vs. 9.8 (9.3-10.2) per 100 person-years). In the adjusted analyses, there was a 
significant interaction between MRA and LVEF groups (p<0.0001), with a lower risk of 
death in MRA treated patients with LVEF < 40% (HR (95% CI) 0.81 (0.75-0.88)) and in 
patients with LVEF 40-49% (0.88 (0.75-1.03)) but not in those with LVEF > 50% (1.29 
(1.09-1.53)) (Figure 13). 
Figure 12  Mortality with and without MRA stratified on EF groups 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
When the patients were divided into presence or not of CKD, MRA was associated with a 
lower mortality rate in patients with CKD (21.5 (20.0-23.1) vs. 26.9 (26.4-27.5) per 100 
person-years), but not in patients without CKD (10.6 (9.7-11.5) vs. 10.7 (10.4-11.0) per 100 
person-years). After adjustment there was no significant interaction between MRA and CKD 
(p=0.46) and there was no difference regarding the association between MRA treatment and 
outcome in patients with (HR (95% CI) 0.92 (0.85-0.99)) and without (0.96 (0.88-1.05)) 
CKD (Figure 13). 
Löfman et al, JAHA 2018. Reproduced with permission from Wiley 
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A sensitivity analysis, including only complete cases in the adjusted analyses, showed similar 
results with a significant interaction between MRA and LVEF, whereas there was no such 
interaction between MRA and CKD.     
Figure 13 Mortality risk with MRA use overall and stratified for LVEF and CKD 
        
 
 
 
 
 
 
 
 
 
 
 
 
Löfman et al, JAHA 2018. Reproduced with permission from Wiley 
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DISCUSSION 
Our main findings were that both CKD and WRF were common in unselected HF patients 
and most common in HFpEF. CKD and WRF were associated with similar co-variates in the 
different EF groups and both were strongly associated with long-term prognosis. In HFpEF 
the prognostic impact of CKD and WRF however was less strong than in HFrEF and 
HFmrEF. In unselected MI patients with HF, MRA was associated with better long-term 
survival in patients with reduced but not in preserved EF, while the association between 
MRA use and outcome was similar regardless of presence or not of CKD. 
  
Prevalence of renal dysfunction 
The majority of HF patients have one or more comorbidities, CKD being most common 
followed by diabetes and anemia (51). The large meta-analysis of Damman et al. 2014 
examining 57 studies of HF and including both RCTs, cohorts and registries, found a 
prevalence of CKD of 32% (5). In study I the prevalence of eGFR < 60 ml/min/1.73m2 was 
higher (51%), reflecting a real life HF population. In studies of AHF the prevalence of renal 
dysfunction is higher than in studies of CHF (5). In the American database ADHERE of 
AHF, the majority of patients had significant impairment of the kidney function (7). In the 
setting of AHF the predominantly driving force of renal impairment seem to be acute 
congestion with high CVP (1).  CHF has been more studied than AHF and here the 
pathogenesis seems more complex and the reduction in renal blood flow of more importance 
with RAAS inhibitors partly blocking the kidney autoregulation (107).  In study I a majority 
of patients with reduced renal function had HF with duration over 6 months. As many 
patients have an AHF incident on top of CHF, there is probably an overlap in the 
pathogenesis of acute and chronic HF.  
The prevalence of renal insufficiency was found to be similar in the different EF groups in 
earlier registry data (83). Study II was the first large, generalizable, long term, 
comprehensive study of CKD in HFpEF, HFmrEF and HFrEF.  We found that CKD was 
most common in HFpEF with a prevalence of 56%. This was higher than earlier noted and 
consistent with the unselective nature of SwedeHF compared to other registries (2, 83).         
WRF has mostly been studied in acute hospitalized patients and less is known about the risk 
of long-term WRF after discharge. In study III we found that WRF was common and the 
cumulative incidence increased in HF both after discharge from hospital and in out-patients. 
During follow-up, half of the patients had an eGFR reduction of over 25% within two years 
and one quarter of the patients had a reduction of more than 50%. As with CKD, there was a 
higher risk for WRF in patients with HFpEF than in HFmrEF and HFrEF.   
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Associations with renal dysfunction 
In study I the patients with lower kidney function were older, had more often hypertension, 
diabetes mellitus, cardiovascular disease, long duration of HF and more severe NYHA class 
in keeping with previous studies (55, 86).  
Renal dysfunction and HF potentiate each other by cardiorenal mechanisms and share similar 
risk factors.  Diabetes and hypertension are (among RAAS and sympathetic activation, NO 
balance and inflammation) often referred to as cardiorenal connectors (1, 108). Both diabetes 
and hypertension are part of the pathogenesis in cardiorenal syndrome and promotes CKD 
disease progression by arteriosclerosis, tubular damage, albuminuria and nephron loss (109, 
110). 
In study II the HFpEF population was older, more often female, had more comorbidity, was 
more often included at hospitalization; all known risk factors for both HF and CKD (7, 54, 
60). In study II there were interestingly in all three EF categories, almost similar associations 
between baseline characteristics and CKD after multivariable adjustments. Hemoglobin was 
independently associated with CKD, as was diabetes and hypertension. Even though the risk 
factors for CKD were similar in the different EF groups, the mechanisms leading to CKD and 
the impact of CKD in the different EF groups may vary.   
HFrEF and renal dysfunction 
In HFrEF progress of HF is primarily due to loss of cardiomyocytes by ischemic heart 
disease and cardiomyopathies with subsequent RAAS and sympathetic activation and 
remodeling (57). The reduced cardiac function constitutes both forward and backward failure 
(111). Congestion of the kidney by high venous pressure, raised abdominal pressure and low 
stroke volume leads to reduced perfusion pressure in the glomeruli and reduced eGFR (13). 
With kidney congestion and reduced renal blood flow, the circulation in the kidney cortex 
and the tubules will be reduced, leading to varying degrees of tubular damage (112).  
 
HFpEF and renal dysfunction 
In HFpEF the primary mechanism for disease progression is believed to be driven by the 
comorbidities. A new paradigm has been proposed for HFpEF where comorbidities induce an 
inflammatory state with microvascular dysfunction potentially leading to both cardiac and 
renal fibrosis (61, 113, 114). The direction of causality may however be in the opposite 
direction or bidirectional. There is a higher proportion of chronotropic insufficiency in 
HFpEF, which has shown a linear correlation with reduction in eGFR (115). In a study of 
HFpEF and echocardiography, CKD were associated with left atrial, left ventricular and right 
ventricular strain, proposing also a vicious circle where CKD and HFpEF are mutually 
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reinforced (116). There has been an increased understanding of HFpEF, where the 
combination of inflammatory state, hemodynamics and comorbidities is thought to induce 
right ventricular dysfunction which through increased central venous pressure deteriorate the 
kidney function further, explaining the high prevalence of renal dysfunction in HFpEF (64).  
The mechanisms in the progress of CKD in HFpEF seem therefore to be partially overlapping 
with the mechanisms in HFrEF and are accentuated by comorbidities and inflammation.  
HFmrEF and renal dysfunction 
In prior reports, HFmrEF has most often either been excluded as a grey area or included in 
the HFpEF or the HFrEF population (54, 55, 117). In study II we provide a detailed 
description of the HFmrEF group, where many clinical characteristics like age, proportion of 
female and hypertension were at a continuum between HFpEF and HFrEF but some 
characteristics like IHD and valvular disease were more similar to HFrEF than to HFpEF. 
This has later been confirmed in other studies of HFmrEF, where the main findings are that 
HFmrEF is similar to HFrEF regarding genesis of IHD and has a different response to 
treatment compared to HFpEF (118). The mechanism for CKD in HFmrEF is probably 
complex and similar to both HFpEF and HFrEF as HFmrEF is partly a transition between the 
two depending on the actual state of the HF. A proportion of  HFmrEF seems to represent a 
prior or future HFpEF or HFrEF as different studies have shown that in  17-37% LVEF 
deteriorates and in 21-73 % it improves (119, 120). 
In study III we examined the determinants of WRF and found similar associations as with 
CKD.  Even here factors related to more severe HF were associated with WRF; higher age, 
valvular heart disease, registration at discharge from hospitalization vs. out-patient, HF over 6 
months, CRT, NYHA class, anemia, low blood pressure, use of MRAs and diuretics were 
associated with WRF >25% after 1 year. We found few significant differences between the 
EF groups.   
Prognosis 
Patients with more than moderate decrease in kidney function have been excluded from 
clinical trials (57). The degree of kidney dysfunction and the impact of kidney dysfunction on 
outcomes in patients with HF have therefore earlier been under estimated.   
In study I kidney function was strongly associated with short and long term mortality with an 
increasing mortality with decreasing eGFR. At five years, the cumulative probability of death 
was above 60% in those with moderate kidney dysfunction and above 80 % in patients with 
severe kidney dysfunction. The strong association with outcome was evident in all age 
groups, regardless of NYHA class, duration of heart failure, hemoglobin level and presence 
or not of diabetes mellitus. The high mortality in patients with HF and CKD may have 
multiple mechanisms. Both CKD and HF have similar risk factors associated with mortality; 
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like smoking, hyperlipidemia, anemia, hypertension and diabetes (85, 121, 122).  CKD may 
be a marker for more severe heart failure as eGFR decreases with high venous pressure, 
ascites with increased abdominal pressure and forward failure (16, 17). Factors secondary to 
CKD, as endothelial dysfunction, secondary hyperparathyroidism, vascular calcifications, 
increased oxidative stress, chronic inflammation, metabolic acidity, deterioration of calcium-
phosphate and electrolyte balance may also increase mortality (3). Patients with CKD are also 
less likely to receive evidenced based treatment because of fear of WRF and the uncertainty 
regarding optimal treatment doses (57, 123). In study I after adjustments for risk factors and 
factors related to severity of HF, impaired kidney function remained strongly associated with 
mortality confirming results from earlier observations showing that GFR is an independent 
predictor itself for outcome (86). When finally adjusting for treatment in our study, the 
association between kidney function and outcome remained unchanged; indicating that 
suboptimal treatment may not be so important for adverse outcome in patients with HF and 
reduced kidney function. 
In study II CKD was strongly associated with mortality in all EF groups in line with earlier 
studies (5). The impact of CKD on prognosis in the different EF groups has varied according 
to different studies. In the meta-analysis of Damman et al of 80,000 patients, CKD was found 
to be a stronger predictor of death in HFpEF than in HFrEF, while the pooled study of 
McAlister et al. from the MAGGIC meta-analysis showed that renal dysfunction was a 
stronger predictor of all-cause mortality in patients with HFrEF than in HFpEF (5, 89). In 
study II we found in line with the MAGGIC meta-analysis that the mortality risk with CKD 
was lower in HFpEF in both the univariate and multivariate analyses than in the other EF 
groups. As CKD represents one of many comorbidities in HFpEF, the predictive role of 
impaired renal function may therefore be relatively lower in HFpEF than in HFmrEF and 
HFrEF. 
In study III we found a weaker association between WRF and mortality in HFpEF compared 
to HFmrEF and HFrEF. In HFpEF and WRF the prognosis may be more related to 
comorbidities than in HFrEF, where progressive HF with subsequent kidney dysfunction may 
be more pronounced. Study II and III imply that in HFpEF both CKD and WRF are more 
common but seem to be less strongly associated with prognosis. In HFpEF there may be a 
parallel drive of CKD and HF by the comorbidities which lead to renal dysfunction being 
more frequent but less prognostic as it may not reflect a worse cardiac status. Whereas in 
HFrEF and HFmrEF, the kidney dysfunction may be secondary to more advanced HF and 
therefore comes later and is less frequent but once present, associated with greater risk. Even 
though there will be overlaps in the pathogenesis, as HFpEF and HFrEF have mutual 
cardiorenal connectors, this hypothesis may explain the observed differences in prevalence 
and prognosis in renal dysfunction between HFpEF and HFrEF . 
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Heart failure treatment and prognosis in different EF groups 
In study IV the main finding was that MRA treatment was associated with a lower mortality 
in MI patients with reduced LVEF (< 40%) but not in patients with preserved LVEF (> 50%). 
Although the number of patients with EF > 50% was small, and we do not know the 
indication for MRA treatment, the finding was noteworthy.  
Earlier studies of MRA treatment in HFrEF are well in line with our results. Both RALES, 
study of spironolactone in patients with severe HF and LVEF < 35% and EMPHASIS-HF, 
study of eplerenone in patients with mild HF and LVEF < 35% found that MRA in addition 
to standard therapy improved survival and morbidity (98, 124).  In EPHESUS similar effects 
was found in patients with acute MI complicated by LVEF < 40% and symptomatic HF or 
diabetes (99). In the STEMI guidelines 2017 MRA has a class I indication in patients with 
MI, HF and LVEF < 40% (125).  As study IV examines MRA treatment in non-selected real-
life patients with acute MI and HF, it is noteworthy that only 19.6% of the patients with 
LVEF < 40% had MRA.  Although this may be explained by the fact that MRA may be 
introduced after up-titration of  ACEi/ARB and therefore prescribed after discharge from 
hospital, similar numbers have been noted in the US were only one out of seven eligible 
patients were prescribed MRA at discharge (126). 
On the contrary, when looking at LVEF > 50%, the means for comparing our results in the 
patients with preserved LVEF are lacking. There are no studies of MRA use in MI patients 
with HF and LVEF > 50%. We may compare our findings with the results from the TOPCAT 
study of aldosterone antagonists in HFpEF (100). This study failed to show a reduction in the 
composite endpoint of cardiovascular death, aborted cardiac arrest and hospitalization with 
MRA, although a post-hoc analysis showed regional differences with benefits of 
spironolactone in the American patients (101).  In study IV we found that patients with 
LVEF 40-49% had a tendency to lower mortality risk, which is in line with another sub-
analysis from TOPCAT showing a potentially stronger beneficial effect at the lower end of 
the EF spectrum (127). The difference in survival with MRA treatment in LVEF > 50% and 
LVEF < 40% is intriguing and also in line with earlier meta-analysis of MRA treatment in HF 
(128). Once again we are reminded that HFpEF and HFrEF are two different phenotypes with 
different pathogenesis. In HFpEF, pathogenesis is driven by comorbidities and inflammation 
while HFrEF are characterized by loss of myocytes due to ischemic heart disease or 
cardiomyopathies with neurohormonal activation (57, 61). Until now, all RCTs of HF 
treatment in HFpEF have failed to show improved survival (129). Aldosterone is part of the 
RAAS and RAAS blockade have not shown to have the same benefit in HFpEF as in HFrEF. 
Treatment with candesartan in CHARM-preserved did not reduce outcome (cardiovascular 
death and HF hospitalization) (130), indicating that neurohormonal activation is not as 
dominant part of pathogenesis in HFpEF as in HFrEF.  
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There may be differences in the comorbidities in HFpEF compared to HFrEF and also in the 
severity of HF in HFpEF that may affect the response to treatment. In a sub-analysis of  
Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-PRESERVE), only 
HFpEF patients with modest NT-proBNP levels seemed to benefit from irbesartan suggesting 
that HFpEF patients with more advanced disease with the highest NT-proBNP and the worst 
prognosis were beyond potential medical treatment (131).     
Patients with HFpEF have been found to die less from cardiovascular death and sudden 
cardiac death than HFrEF (132). This may also partly explain the lack of benefit of MRA in 
HFpEF as MRA has shown to reduce the risk of arrhythmias (98, 133).  
Heart failure treatment in patients with CKD 
The other main finding in study IV was that in patients with HF and CKD, there was no 
difference in mortality risk with MRA treatment compared to untreated patients. Patients with 
CKD have an increased mortality risk, predominantly from cardiovascular disease (134).  As 
fibrosis of the heart, vessels and kidney are common in CKD, MRA represent a potential 
option to prevent cardiovascular complications (135). A meta-analysis of 12 CKD studies and 
over 4,000 patients showed that MRA treatment did benefit CKD patients regarding left 
ventricular muscular mass, all-cause mortality and cardio-vascular events and even patients in 
hemodialysis have been found to have reduced morbidity and mortality with MRA treatment 
(136, 137). There is a risk for hyperkalemia and WRF with MRA, which may explain why 
patients with CKD in the clinic often have MRA treatment withheld. Sub-analyses of 
EMPHASIS-HF and RALES found that MRA was of survival benefit despite WRF and 
surprisingly the greatest benefit was seen in patients with reduced eGFR (102, 138). Another 
sub-analysis of EMPHASIS-HF found MRA use to be efficient and safe in risk patients when 
they were well monitored (139). Criticism have been that in RCTs of MRA in addition to 
ACEi and beta blockers, the patients included are already selected as they have tolerated  
ACEi /ARB without hyperkalemia and  there is therefore a potentially higher risk in 
unselected patients (139). In this setting future treatment with potassium binders may be 
feasible and facilitate MRA treatment (140). Even though our knowledge of MRA treatment 
in more pronounced kidney dysfunction is sparse, MRA seem to be underused, as only 8.6% 
of the patient with CKD had MRA. A recent study confirms that the most common factor 
associated to MRA underuse in HFrEF patients was CKD, this included even patients with 
only modest reduction of renal function (eGFR 30-59 ml/min/m2) where MRA was indicated 
(141). In study IV we examined an unselected real-life population and found that there was 
no higher mortality with MRA treatment in patients with CKD indicating that MRA may be 
used in MI patients with HF and reduced kidney function. 
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Limitations 
Both SwedeHF and Swedeheart are registries that reflect clinical practice. There may still be 
a certain selection of patients, as some patients may not have been transferred to the 
cardiology units and included in the registers because of frailty, co-morbidity or other reasons 
which may affect the generalizability of our studies. All studies were observational therefore 
causality cannot be proven. In all regression analyses we adjusted for a large number of 
confounders, but residual confounding may still exist due to unmeasured factors that could 
not be adjusted for. 
The diagnosis of HFpEF is more contentious than diagnosing HFrEF. The criteria for 
diastolic dysfunction have changed over the years (142). Patients with CKD may have fluid 
retention and high filling pressures making it difficult to distinguish CKD from HFpEF (143). 
Many patients with diastolic dysfunction may also have alternative explanations for their 
dyspnea, such as obesity, pulmonary disease and ischemia (144). Taken together patients 
diagnosed with HFpEF are a heterogeneous group in which some may not have HF at all. 
However the patients that get a diagnosis of HFpEF may have a more severe HF than patients 
with HFrEF when they are taken into the cardiac units. This may have had an effect on the 
prevalence and prognosis of CKD in these patients. 
In study IV, in analyses of MI and EF, a slightly reduced EF may be intermittent due to 
stunning, and the HF signs may have been temporary which is why we have to be cautious to 
extrapolate our results to a population of CHF. Regarding the MRA use; we do not know for 
sure if the patients continued with their medication during follow-up or if untreated patients 
were prescribed MRA later.  
The EF measurements were according to local practice and not according to a core 
laboratory. 
Even though there are limitations, study I and II included over 40,000 HF patients in Sweden 
during more than 10 years, study III included the majority of hospitalized HF patients in 
Stockholm during 5 years and study IV included almost all patients with acute MI and HF 
for a period of 10 years in a whole country, leading us to believe that the results should be 
highly generalizable. 
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CONCLUSIONS 
In unselected HF patients: 
• Half of the patients have at least a moderate decrease in kidney function classified as CKD. 
• Within two years, over half of the patients will have WRF of at least 25%. 
• CKD and WRF are common in all EF groups and most common in patients with HFpEF. 
• CKD is associated with similar covariates regardless of EF. 
• Variables related to more severe HF are predictive of WRF in all EF groups. 
• There is a strong graded association between renal dysfunction and both short- and long-
term outcome. 
• CKD is strongly associated with outcome in all EF groups, but less so in HFpEF than in 
HFmrEF and HFrEF. 
• WRF is a strong negative prognostic factor in all EF groups, although in HFpEF only in 
patients with the most severe WRF. 
In unselected patients with MI and HF: 
• MRA may be underused in patients with reduced EF. 
• MRA use is associated with better survival in patients with reduced EF but not in patients 
with preserved EF. 
• The association between MRA use and outcome seems to be similar regardless of presence 
or not of CKD. 
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Clinical perspectives 
As CKD is the strongest risk factor in HF and WRF may have an impact on survival over 
many years it is an essential goal to preserve the kidney function in all HF patients.  This 
includes early relief of decongestion when the patient is admitted to hospital and avoiding 
unnecessary examinations with contrast and nephrotoxic agents. As a simple measurement of 
creatinine is an indicator of patient prognosis, it is important to be observant to the laboratory 
tests. Estimation of GFR is easy and of uttermost value. Patients with HF and moderate renal 
dysfunction (eGFR 30-59 ml/min/1.73 m2) should not have optimal HF treatment, including 
MRA withheld. Collaboration with the nephrologists is important as are close-follow-up of 
the patients with laboratory controls after adjustment of the medication. Identifying patients 
at risk to prevent WRF may help in preserving renal function and improve clinical outcome. 
We still lack guideline recommended treatment in HFpEF, which is why it is essential to 
identify and treat the patients’ comorbidities to decrease the risk of progressive renal 
dysfunction. 
As CKD patients are at high risk of cardiovascular disease, early detection of cardiac 
symptoms and treatment of risk factors are important.  Even here is a close collaboration with 
the cardiologist necessary so that the patients are not excluded from examinations and receive 
optimal treatment to avoid ischemic events and HF.  
Future studies 
The renocardial part of CRS is less well described. It is unclear why some patients with CKD 
develop HFpEF with a transition towards a hypertrophic phenotype while others develop 
HFrEF in an earlier stage. These differences may be due to hemodynamic differences in 
filling pressures, preload and afterload, in inflammatory state and possibly underlying 
structural and premorbid differences that we do not know of and are in need of further 
studies.  
The potential of reversing HF and CKD in CRS is also less well studied.  Studies of kidney 
transplantation patients with HF have shown that EF may be improved when restoring renal 
function but we are in need of more knowledge of the pathophysiologic factors involved to be 
able to optimize patient selection (145).  
Study IV implies that MRA may be used in the presence of CKD. Hopefully future RCTs of 
HF medications will be able to include patients with more severe renal dysfunction as there is 
a need for evidenced based treatment of patients with CKD. 
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